AllCereno Scientific Record date for distribution of warrants of series TO1 and TO2 to current shareholders is set for October 9, 2020 FRI, OCT 02, 2020 17:41 CET As previously announced, the Board of Directors of Cereno…skylarbennethumOctober 2, 2020
AllCereno Scientific Cereno Scientific publishes interim report for Q3 2020 (1 January – 30 September 2020) THU, NOV 19, 2020 08:33 CET The Board and Chief Executive Officer of Cereno Scientific…skylarbennethumSeptember 30, 2020
AllCereno Scientific Cereno Scientific enters rare disease space with lead drug candidate CS1 TUE, SEP 29, 2020 17:30 CET Cereno Scientific today announced that the company will advance…skylarbennethumSeptember 29, 2020
AllNexImmune NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML) Company is using its Artificial Immune Modulation (AIM) nanoparticle technology to develop T cell immunotherapies for patients with relapsed and/or refractory hematologic…skylarbennethumSeptember 23, 2020
All Bayer and Northpond Ventures Lead USD 55 million Series A Financing Round for Triumvira Immunologics Leaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno…dantetzlAugust 27, 2020
All Bayer and Northpond Ventures Lead USD 55 million Series A Financing Round for Triumvira Immunologics Leaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno…skylarbennethumAugust 27, 2020